Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$40.91 +0.6%	$38.95	$31.72 ▼ $42.63	$82.74B	0.53	3.63 million shs	3.07 million shs
INSM Insmed	$145.03 +0.2%	$125.04	$60.40 ▼ $149.08	$30.60B	0.96	2.15 million shs	2.89 million shs
SNY Sanofi	$47.01 -1.3%	$48.46	$44.73 ▼ $60.12	$116.98B	0.51	2.86 million shs	2.62 million shs
TAK Takeda Pharmaceutical	$15.04 -0.2%	$14.82	$12.80 ▼ $15.69	$47.92B	0.22	2.91 million shs	1.35 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	+0.69%	+1.49%	+1.91%	+5.83%	+0.27%
INSM Insmed	+0.19%	+1.32%	+9.97%	+36.95%	+95.43%
SNY Sanofi	-1.32%	+0.84%	-8.45%	-2.91%	-18.43%
TAK Takeda Pharmaceutical	-0.23%	-0.30%	-3.02%	-0.40%	+1.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$40.91 +0.6%	$38.95	$31.72 ▼ $42.63	$82.74B	0.53	3.63 million shs	3.07 million shs
INSM Insmed	$145.03 +0.2%	$125.04	$60.40 ▼ $149.08	$30.60B	0.96	2.15 million shs	2.89 million shs
SNY Sanofi	$47.01 -1.3%	$48.46	$44.73 ▼ $60.12	$116.98B	0.51	2.86 million shs	2.62 million shs
TAK Takeda Pharmaceutical	$15.04 -0.2%	$14.82	$12.80 ▼ $15.69	$47.92B	0.22	2.91 million shs	1.35 million shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	+0.69%	+1.49%	+1.91%	+5.83%	+0.27%
INSM Insmed	+0.19%	+1.32%	+9.97%	+36.95%	+95.43%
SNY Sanofi	-1.32%	+0.84%	-8.45%	-2.91%	-18.43%
TAK Takeda Pharmaceutical	-0.23%	-0.30%	-3.02%	-0.40%	+1.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSK GSK	1.86	Reduce	$37.38	-8.64% Downside
INSM Insmed	2.94	Moderate Buy	$139.86	-3.57% Downside
SNY Sanofi	3.11	Buy	$62.67	33.30% Upside
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest INSM, SNY, GSK, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2025	INSM Insmed	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$125.00 ➝ $172.00
9/8/2025	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$56.00 ➝ $58.00
9/3/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$140.00 ➝ $171.00
9/2/2025	SNY Sanofi	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
8/21/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$126.00 ➝ $144.00
8/21/2025	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/20/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$111.00 ➝ $135.00
8/20/2025	INSM Insmed	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/14/2025	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$126.00 ➝ $139.00
8/14/2025	INSM Insmed	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$121.00 ➝ $145.00
8/13/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$114.00 ➝ $142.00

(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSK GSK	$40.10B	2.08	$5.61 per share	7.29	$8.07 per share	5.07
INSM Insmed	$363.71M	84.29	N/A	N/A	$1.60 per share	90.64
SNY Sanofi	$44.46B	2.60	$5.26 per share	8.94	$33.20 per share	1.42
TAK Takeda Pharmaceutical	$30.09B	1.59	$3.17 per share	4.74	$14.39 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSK GSK	$3.29B	$2.16	18.94	8.80	2.03	10.81%	49.22%	11.31%	10/29/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.71	N/A	N/A	N/A	-259.82%	-195.37%	-49.49%	10/30/2025 (Estimated)
SNY Sanofi	$6.02B	$4.16	11.30	9.90	1.12	21.47%	16.86%	9.63%	10/24/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.30	50.12	9.11	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)

Latest INSM, SNY, GSK, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	INSM Insmed	-$1.30	-$1.70	-$0.40	-$1.70	$104.06 million	$107.42 million
7/31/2025	Q2 2025	SNY Sanofi	$0.96	$0.90	-$0.06	$1.84	$9.91 billion	$11.34 billion
7/30/2025	Q2 2025	GSK GSK	$1.12	$1.23	+$0.11	$0.94	$7.92 billion	$10.64 billion
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSK GSK	$1.68	4.11%	N/A	77.78%	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.60	3.40%	N/A	38.46%	N/A
TAK Takeda Pharmaceutical	$0.55	3.66%	N/A	183.33%	N/A

Latest INSM, SNY, GSK, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSK GSK	1.07	0.87	0.57
INSM Insmed	0.45	6.68	6.33
SNY Sanofi	0.19	1.27	0.94
TAK Takeda Pharmaceutical	0.60	1.16	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GSK GSK	15.74%
INSM Insmed	N/A
SNY Sanofi	14.04%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
GSK GSK	10.00%
INSM Insmed	3.00%
SNY Sanofi	1.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GSK GSK	68,629	2.03 billion	1.83 billion	Optionable
INSM Insmed	1,271	211.38 million	205.03 million	Optionable
SNY Sanofi	82,878	2.46 billion	2.43 billion	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

INSM, SNY, GSK, and TAK Headlines

Recent News About These Companies

Pharma Pulse: CDC Delays Hepatitis B Vaccine Vote, Value-Based Care Improves Senior Access, and Takeda Tests Wind-Powered Shipping

September 22 at 8:20 AM | pharmaceuticalcommerce.comP

Pharma Pulse: CDC Delays Hepatitis B Vaccine Vote, Value-Based Care Improves Senior Access, and Takeda Tests Wind-Powered Shipping

September 22 at 8:20 AM | pharmaceuticalcommerce.comP

22,734 Shares in Takeda Pharmaceutical Co. $TAK Bought by Sivia Capital Partners LLC

September 19, 2025 | marketbeat.com

IBD 101: Intensive Course for GI Fellows Boosts Clinical Confidence

September 18, 2025 | medscape.comM

Gastroparesis Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome ...

September 18, 2025 | theglobeandmail.com

Experimental narcolepsy drugs bring hope to patients: ‘as close as one could get to living a near-normal life’

September 17, 2025 | statnews.comS

Takeda, Asian Hospital partner to expand access to life saving medicines for rare conditions

September 17, 2025 | businessmirror.com.phB

Takeda Flat on Hookup with VELA

September 16, 2025 | baystreet.ca

‘As close as one could get to living a near-normal life’: Experimental narcolepsy drugs bring hope to patients

September 16, 2025 | bostonglobe.comB

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

September 15, 2025 | finance.yahoo.com

Baird Financial Group Inc. Invests $276,000 in Takeda Pharmaceutical Co. $TAK

September 14, 2025 | marketbeat.com

Takeda poaches top Lilly exec; Maze soars on early PKU drug data

September 12, 2025 | biopharmadive.comB

Antibody Drug Conjugates Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Bristol Myers Squibb, GSK, MBrace therapeutics, Oxford Biotherapeutics ...

September 11, 2025 | theglobeandmail.com

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

September 11, 2025 | pharmiweb.comP

Takeda Pharmaceutical (NYSE:TAK) Sets New 1-Year High - Should You Buy?

September 10, 2025 | marketbeat.com

CVS Sues Takeda, Bora Units Claiming Collusion on Reflux Drug

September 9, 2025 | news.bloomberglaw.comN

Nikkei ends lower on yen strength, profit-taking after crossing 44,000

September 9, 2025 | msn.com

Japan's Nikkei rises to 44,000 for first time on trade, spending optimism

September 9, 2025 | msn.com

Assessing Takeda Stock After Recent 6% Jump and New FDA Approval for HyQvia Expansion

September 9, 2025 | finance.yahoo.com

Takeda nears first therapy for root cause of narcolepsy

September 9, 2025 | japantimes.co.jpJ

Promising Phase 3 Results for Takeda’s Oveporexton Boost Buy Rating

September 9, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM, SNY, GSK, and TAK Company Descriptions

GSK NYSE:GSK

$40.91 +0.24 (+0.59%)

Closing price 09/22/2025 03:59 PM Eastern

Extended Trading

$40.96 +0.05 (+0.12%)

As of 08:08 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Insmed NASDAQ:INSM

$145.03 +0.27 (+0.19%)

Closing price 09/22/2025 04:00 PM Eastern

Extended Trading

$144.62 -0.41 (-0.28%)

As of 08:00 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Sanofi NASDAQ:SNY

$47.01 -0.63 (-1.32%)

Closing price 09/22/2025 04:00 PM Eastern

Extended Trading

$47.04 +0.04 (+0.07%)

As of 08:07 AM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical NYSE:TAK

$15.04 -0.03 (-0.17%)

Closing price 09/22/2025 03:58 PM Eastern

Extended Trading

$15.02 -0.02 (-0.13%)

As of 08:00 AM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INSM, SNY, GSK, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INSM, SNY, GSK, and TAK Earnings

Compare Dividends

Latest INSM, SNY, GSK, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INSM, SNY, GSK, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM, SNY, GSK, and TAK Company Descriptions

GSK NYSE:GSK

Insmed NASDAQ:INSM

Sanofi NASDAQ:SNY

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INSM, SNY, GSK, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INSM, SNY, GSK, and TAK Earnings

Compare Dividends

Latest INSM, SNY, GSK, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INSM, SNY, GSK, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM, SNY, GSK, and TAK Company Descriptions

GSK NYSE:GSK

Insmed NASDAQ:INSM

Sanofi NASDAQ:SNY

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools